{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:57:08Z","timestamp":1760151428538,"version":"build-2065373602"},"reference-count":38,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Applied Sciences"],"abstract":"<jats:p>Adherence to topical treatments is low and is known to be influenced by the vehicle properties. Betamethasone dipropionate (BD) is an anti-inflammatory steroid, used in psoriasis treatment in the form of an ointment, cream, or solution. The aim of this work was to develop a new vehicle for BD, focusing on the preferences of patients with psoriasis as a strategy to improve treatment adherence. Two vehicles with an aqueous external phase were explored: an emulgel and a hydrogel based on a cyclodextrin inclusion complex used to improve the aqueous solubility of BD. Since BD solubilization was not fully achieved in the hydrogel, only the emulgel was selected for further characterization. This new vehicle (emulgel) is characterized by its white, shiny appearance and good spreading properties. In comparison with petrolatum, a lower residue, higher evaporation rate, lower stickiness, and reduced ability to stain polyester fabric were observed. This vehicle also showed shear thinning behavior. The impact of this new vehicle on adherence to topical treatments should be further confirmed in clinical settings.<\/jats:p>","DOI":"10.3390\/app12073260","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T12:20:25Z","timestamp":1648038025000},"page":"3260","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Design of an Emulgel for Psoriasis Focused on Patient Preferences"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0258-9472","authenticated-orcid":false,"given":"Rita Sanches","family":"Oliveira","sequence":"first","affiliation":[{"name":"Biomedical Research Centre CEBIMED\/Research Centre of the Fernando Pessoa Energy, Environment and Health Research Unit FP-ENAS, Faculty of Health Sciences, University of Fernando Pessoa, 4249-004 Porto, Portugal"}]},{"given":"Diva Ferraz","family":"da Silva","sequence":"additional","affiliation":[{"name":"UCIBIO\/REQUIMTE, MedTech, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5348-8431","authenticated-orcid":false,"given":"Sandra","family":"Mota","sequence":"additional","affiliation":[{"name":"UCIBIO\/REQUIMTE, MedTech, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"},{"name":"Associate Laboratory i4HB\u2014Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8981-231X","authenticated-orcid":false,"given":"Jorge","family":"Garrido","sequence":"additional","affiliation":[{"name":"CIQUP-IMS, Department of Chemical Engineering, School of Engineering (ISEP), Polytechnic of Porto, 4200-072 Porto, Portugal"}]},{"given":"Ermelinda Manuela","family":"Garrido","sequence":"additional","affiliation":[{"name":"CIQUP-IMS, Department of Chemical Engineering, School of Engineering (ISEP), Polytechnic of Porto, 4200-072 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9518-8397","authenticated-orcid":false,"given":"Jos\u00e9 Manuel Sousa","family":"Lobo","sequence":"additional","affiliation":[{"name":"UCIBIO\/REQUIMTE, MedTech, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"},{"name":"Associate Laboratory i4HB\u2014Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1498-048X","authenticated-orcid":false,"given":"Isabel Filipa","family":"Almeida","sequence":"additional","affiliation":[{"name":"UCIBIO\/REQUIMTE, MedTech, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"},{"name":"Associate Laboratory i4HB\u2014Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Menditto, E., Orlando, V., De Rosa, G., Minghetti, P., Musazzi, U.M., Cahir, C., Kurczewska-Michalak, M., Kardas, P., Costa, E., and Sousa Lobo, J.M. (2020). Patient Centric Pharmaceutical Drug Product Design-The Impact on Medication Adherence. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12010044"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40257-017-0272-2","article-title":"Development and Validation of a Novel Questionnaire for Adherence with Topical Treatments in Psoriasis (QATOP)","volume":"18","author":"Teixeira","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2008.03.045","article-title":"One in 3 prescriptions are never redeemed: Primary nonadherence in an outpatient clinic","volume":"59","author":"Storm","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/1346-8138.12804","article-title":"Poor adherence to medication as assessed by the Morisky Medication Adherence Scale-8 and low satisfaction with treatment in 237 psoriasis patients","volume":"42","author":"Saeki","year":"2015","journal-title":"J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1468-3083.2011.04440.x","article-title":"Patient preferences for psoriasis treatments: Impact of treatment experience","volume":"27","author":"Schaarschmidt","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-3083.2005.01329.x","article-title":"How patients experience psoriasis: Results from a European survey","volume":"19","author":"Fouere","year":"2005","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1208\/s12248-016-9938-6","article-title":"Defining Patient Centric Pharmaceutical Drug Product Design","volume":"18","author":"Stegemann","year":"2016","journal-title":"AAPS J."},{"key":"ref_8","unstructured":"Svendsen, M.T., Feldman, S.R., Tiedemann, S.N., Sorensen, A.S.S., Rivas, C.M.R., and Andersen, K.E. (2019). Psoriasis patient preferences for topical drugs: A systematic review. J. Dermatol. Treat., 1\u20136."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/09546634.2018.1544410","article-title":"Patient preferences for attributes of topical anti-psoriatic medicines","volume":"30","author":"Vasconcelos","year":"2019","journal-title":"J. Dermatol. Treat."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1039\/D1NR06001E","article-title":"Hydrogel-mediated topical delivery of steroids can effectively alleviate psoriasis via attenuating the autoimmune responses","volume":"14","author":"Rana","year":"2022","journal-title":"Nanoscale"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Fabbrocini, G., De Simone, C., Dapavo, P., Malagoli, P., Martella, A., and Calzavara-Pinton, P. (2022). Long-term maintenance treatment of psoriasis: The role of calcipotriol\/betamethasone dipropionate aerosol foam in clinical practice. J. Dermatol. Treat., 1\u20138. ahead of print.","DOI":"10.1080\/09546634.2021.1998310"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/jdv.17734","article-title":"A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis","volume":"36","author":"Pinter","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s13555-016-0119-4","article-title":"Patient Preferences for Topical Psoriasis Treatments are Diverse and Difficult to Predict","volume":"6","author":"Iversen","year":"2016","journal-title":"Dermatol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Boeri, M., Saure, D., Schuster, C., Hill, J., Guerreiro, M., Klein, K., and Hauber, B. (2021). Impact of clinical and demographic characteristics on patient preferences for psoriasis treatment features: Results from a discrete-choice experiment in a multicountry study. J. Dermatol. Treat., 1\u20138.","DOI":"10.1080\/09546634.2020.1869145"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s41669-018-0104-1","article-title":"Patient and Physician Preferences for Therapy Characteristics for Psoriasis: A Discrete Choice Experiment in Japan","volume":"3","author":"Bolt","year":"2019","journal-title":"PharmacoEconomics-Open"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/09546634.2018.1473837","article-title":"Patients preferences for different corticosteroid vehicles are highly variable","volume":"31","author":"Felix","year":"2020","journal-title":"J. Dermatol. Treat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00403-018-1808-x","article-title":"Treatment preferences and treatment satisfaction among psoriasis patients: A systematic review","volume":"310","author":"Florek","year":"2018","journal-title":"Arch. Dermatol. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/jdv.14515","article-title":"Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: Randomized phase IIIb PSO-INSIGHTFUL study","volume":"31","author":"Hong","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_19","first-page":"46","article-title":"Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis","volume":"94","author":"Eastman","year":"2014","journal-title":"Cutis"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2165\/00128071-200304040-00001","article-title":"Patients\u2019 vehicle preference for corticosteroid treatments of scalp psoriasis","volume":"4","author":"Feldman","year":"2003","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_21","first-page":"327","article-title":"Patients with psoriasis prefer solution and foam vehicles: A quantitative assessment of vehicle preference","volume":"70","author":"Housman","year":"2002","journal-title":"Cutis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ad.2012.12.005","article-title":"Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: A Delphi study with an expert panel and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology","volume":"104","author":"Puig","year":"2013","journal-title":"Actas Dermo-Sifiliogr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"102156","DOI":"10.1016\/j.jddst.2020.102156","article-title":"Technological evolution of cyclodextrins in the pharmaceutical field","volume":"61","author":"Riascos","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jconrel.2013.06.030","article-title":"Recent expansions in an emergent novel drug delivery technology: Emulgel","volume":"171","author":"Ajazuddin","year":"2013","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.drudis.2015.11.016","article-title":"Cyclodextrins in pharmaceutical formulations II: Solubilization, binding constant, and complexation efficiency","volume":"21","author":"Jambhekar","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3389\/fphar.2020.01105","article-title":"Hyaluronic Acid-Mediated Drug Delivery System Targeting for Inflammatory Skin Diseases: A Mini Review","volume":"11","author":"How","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Fluhr, J.W., Berardesca, E., and Darlenski, R. (2012). Psoriasis and dry skin: The impact of moisturizers. Treatment of Dry Skin Syndrome: The Art and Science of Moisturizers, Springer.","DOI":"10.1007\/978-3-642-27606-4_19"},{"key":"ref_28","first-page":"211","article-title":"Moisturizing cream ameliorates dryness and desquamation in participants not receiving topical psoriasis treatment","volume":"82","author":"Draelos","year":"2008","journal-title":"Cutis"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1208\/s12249-010-9447-3","article-title":"Characterization of Polymeric Solutions as Injectable Vehicles for Hydroxyapatite Microspheres","volume":"11","author":"Oliveira","year":"2010","journal-title":"Aaps Pharmscitech"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/jtxs.12442","article-title":"Recognition of the great successes of food texture research","volume":"50","author":"Chen","year":"2019","journal-title":"J. Texture Stud."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.msec.2015.10.038","article-title":"Strontium-rich injectable hybrid system for bone regeneration","volume":"59","author":"Neves","year":"2016","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3109\/03639045.2013.850712","article-title":"Characterization of an antioxidant surfactant-free topical formulation containing Castanea sativa leaf extract","volume":"41","author":"Almeida","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/jbm.b.31066","article-title":"Injectability of a bone filler system based on hydroxyapatite microspheres and a vehicle with in situ gel-forming ability","volume":"87","author":"Oliveira","year":"2008","journal-title":"J. Biomed. Mater. Res. Part B Appl. Biomater."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1002\/jps.10195","article-title":"Examination of the flow rheological and textural properties of polymer gels composed of poly(methylvinylether-co-maleic anhydride) and poly(vinylpyrrolidone): Rheological and mathematical interpretation of textural parameters","volume":"91","author":"Jones","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1023\/A:1012091231023","article-title":"Textural analysis and flow rheometry of novel, bioadhesive antimicrobial oral gels","volume":"14","author":"Jones","year":"1997","journal-title":"Pharm. Res."},{"key":"ref_36","first-page":"384","article-title":"Mechanical properties of topical products containing bethametasone: Implications for adherence to treatment in psoriasis","volume":"34","author":"Teixeira","year":"2012","journal-title":"Int. J. Cosmet. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1745-459X.2006.00049.x","article-title":"Estimation of hedonic responses from descriptive skin sensory data by chi-square minimization","volume":"21","author":"Almeida","year":"2006","journal-title":"J. Sens. Stud."},{"key":"ref_38","first-page":"242","article-title":"Pooled Analysis Demonstrating Superior Patient- Reported Psoriasis Treatment Outcomes for Calcipotriene\/Betamethasone Dipropionate Cream Versus Suspension\/Gel","volume":"21","author":"Armstrong","year":"2022","journal-title":"J. Drugs Dermatol."}],"container-title":["Applied Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3417\/12\/7\/3260\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:41:41Z","timestamp":1760136101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3417\/12\/7\/3260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,23]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["app12073260"],"URL":"https:\/\/doi.org\/10.3390\/app12073260","relation":{},"ISSN":["2076-3417"],"issn-type":[{"type":"electronic","value":"2076-3417"}],"subject":[],"published":{"date-parts":[[2022,3,23]]}}}